Enhanced MET Translation and Signaling Sustains K-Ras–Driven Proliferation under Anchorage-Independent Growth Conditions
Authors:
Open Access
- 14 July 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (14) , 2851-2862
Abstract
Oncogenic K-Ras mutation occurs frequently in several types of cancers, including pancreatic and lung cancers. Tumors with K-Ras mutation are resistant to chemotherapeutic drugs as well as molecular targeting agents. Although numerous approaches are ongoing to find effective ways to treat these tumors, there are still no effective therapies for K-Ras mutant cancer patients. Here we report that K-Ras mutant cancers are more dependent on K-Ras in anchorage-independent culture conditions than in monolayer culture conditions. In seeking to determine mechanisms that contribute to the K-Ras dependency in anchorage-independent culture conditions, we discovered the involvement of Met in K-Ras–dependent, anchorage-independent cell growth. The Met signaling pathway is enhanced and plays an indispensable role in anchorage-independent growth even in cells in which Met is not amplified. Indeed, Met expression is elevated under anchorage-independent growth conditions and is regulated by K-Ras in a MAPK/ERK kinase (MEK)-dependent manner. Remarkably, in spite of a global downregulation of mRNA translation during anchorage-independent growth, we find that Met mRNA translation is specifically enhanced under these conditions. Importantly, ectopic expression of an active Met mutant rescues K-Ras ablation-derived growth suppression, indicating that K-Ras–mediated Met expression drives “K-Ras addiction” in anchorage-independent conditions. Our results indicate that enhanced Met expression and signaling is essential for anchorage-independent growth of K-Ras mutant cancer cells and suggests that pharmacological inhibitors of Met could be effective for K-Ras mutant tumor patients. Cancer Res; 75(14); 2851–62. ©2015 AACR.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 2012
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical OutcomeJNCI: Journal of the National Cancer Institute, 2012
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersJournal of Clinical Investigation, 2011
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Pancreatic cancer spheres are more than just aggregates of stem marker-positive cellsBioscience Reports, 2010
- The PI3K Pathway As Drug Target in Human CancerJournal of Clinical Oncology, 2010
- HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironmentBreast Cancer Research and Treatment, 2009
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expressionMolecular Oncology, 2007